gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · DTILHealthcareBiotechnology

Precision BioSciences, Inc. Common Stock (DTIL)

$8.12+16.50%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$8.12▲ 21.38% in range
Nov 4, 2025Low $3.57 · High $9.28Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Precision BioSciences closed at $8.12 on Nov 4, up 16.50%, 12.5% below its 52-week closing high. Volume of 402.1K shares was 1.83× its 20-day average (above normal).

Split-adjusted performance: +31.0% over one month, +8.0% over six months, +10.3% over one year.

Short interest was 2.4M shares at the Oct 15 settlement, down 6.3% from the prior report (9.1% of float, 9.3 days to cover).

Market cap$224.1M27.6M shares
Revenue · quarter$0.00−100.0% YoY
Diluted EPS$-1.26—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range3.57 – 9.28−12.5% from high
Volume402.1K1.83× 20-day avg
Volatility · 60d70.1%Annualised
Short % of float9.1%9.4 days to cover
Net cash$65.1MCash $87.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.7%1M +31.0%3M +9.4%6M +8.0%YTD +95.2%1Y +10.3%3Y −12.5%5Y −97.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum73
Revenue growth2
Net margin—
Value (low P/E)—
Size47

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short2.4M−6.3% vs prior
Days to cover9.4Settled Oct 15
% of float9.1%
Short vol. 10d57.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
DTILPrecision BioSciences$8.12+16.50%+8.0%−100.0%——$224.1M
IKTInhibikase Therapeutics$1.57+5.74%−22.1%———$218.4MCompare
PALIPalisade Bio$1.25+1.63%−37.5%—−2114.8%—$217.8MCompare
PLXProtalix BioTherapeutics$2.69+3.07%+33.2%+27.1%19.0%11.4$216.7MCompare
PROKProKidney$1.12+4.67%−42.9%−32.1%−18948.0%—$234.1MCompare
CABACabaletta Bio$1.420.00%−61.9%———$240.8MCompare
ARTVArtiva Biotherapeutics$4.22+0.48%−65.9%———$206.3MCompare
FATEFate Therapeutics$2.09+2.45%−8.7%+9.2%−1448.6%—$250.4MCompare
ALECAlector$2.28+11.22%−11.3%−57.8%−692.5%—$254.6MCompare

News about Precision BioSciences

All news →
CPTx appoints Matt Kane as Chief Financial OfficerGlobeNewswire Inc. · Sep 8, 2026Neutral

Quick answers

What does Precision BioSciences do?
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g.
What is DTIL's market cap?
$224.12M, based on the Nov 4 close of $8.12.
Does Precision BioSciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of DTIL is sold short?
2.4M shares, 9.1% of float, as of Oct 15, 2026.
What sector is DTIL in?
Healthcare, in the Biotechnology industry.

About Precision BioSciences

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

HQ: Durham, NC67 employeesListed Mar 28, 2019precisionbiosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology